Leonard Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health, said in the news release
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." Cell Metabolism
Oral GLP-1 Weight Loss Treatment Weight Loss Without the Weekly Injections Oral GLP-1 weight loss therapy is now available in tablet form at Rejuvime Medical starting at $149.99
With a holistic approach, well look at the full picture of your health concernsfrom weight management to gut health and moreand address the root cause of your symptoms
Beyond weight loss, early exploratory data suggest potential benefits including: Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes Improvements in lipid profiles (cholesterol and triglycerides) Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary Possible cardiovascular benefits
